TWIST1 and prostate carcinoma: miR-186 also regulate Twist expression in the oncogenic processes of the urogenital tract, in particular in ovarian [176] and prostate cancer [177] while miR-300 can inhibit Twist expression leading to EMT blockage in melanoma [178].